Nikhil Kamath
Overview
Explore the profile of Nikhil Kamath including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chuang J, Lide R, Kamath N, Oliveto A, Addicott M
J Addict Dis
. 2025 Jan;
1-5.
PMID: 39834135
Objectives: There is increasing evidence of ketamine's therapeutic potential in reducing substance use in individuals with substance use disorders. However, its effects on tobacco use disorder are unknown. We investigated...
2.
Mai T, Yadav R, Arjomandi A, Jung C, Meier M, Donaldson F, et al.
Clin Pharmacol Drug Dev
. 2024 Apr;
13(6):655-664.
PMID: 38651245
Zinpentraxin alfa is a recombinant form of the human pentraxin-2 that was studied in idiopathic pulmonary fibrosis (IPF). To improve the purity and yield of the drug material, a 2nd-generation...
3.
Richeldi L, Schiffman C, Behr J, Inoue Y, Corte T, Cottin V, et al.
Am J Respir Crit Care Med
. 2024 Feb;
209(9):1132-1140.
PMID: 38354066
A phase II trial reported clinical benefit over 28 weeks in patients with idiopathic pulmonary fibrosis (IPF) who received zinpentraxin alfa. To investigate the efficacy and safety of zinpentraxin alfa...
4.
Mai T, Han L, Hsu J, Kamath N, Pan L
Ther Adv Respir Dis
. 2023 Jul;
17:17534666231181537.
PMID: 37392011
Drug development for idiopathic pulmonary fibrosis (IPF) has been challenging due to poorly understood disease etiology, unpredictable disease progression, highly heterogeneous patient populations, and a lack of robust pharmacodynamic biomarkers....
5.
Szefler S, Roberts G, Rubin A, Zielen S, Kuna P, Alpan O, et al.
Clin Transl Allergy
. 2022 Jul;
12(7):e12176.
PMID: 35846226
Background: Lebrikizumab is a monoclonal antibody that modulates activity of interleukin-13. The Phase 3 ACOUSTICS study assessed lebrikizumab efficacy and safety in adolescents with uncontrolled asthma despite standard-of-care treatment. Methods:...
6.
Raghu G, Hamblin M, Brown A, Golden J, Ho L, Wijsenbeek M, et al.
Respir Res
. 2022 May;
23(1):129.
PMID: 35597980
Background: Recombinant human pentraxin-2 (rhPTX-2) significantly decreased decline in percent predicted forced vital capacity (FVC) and stabilized 6-min walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF) during the...
7.
Sultan P, Kamath N, Carvalho B, Bansal P, Elkhateb R, Dougan S, et al.
Am J Obstet Gynecol MFM
. 2020 Dec;
2(4):100202.
PMID: 33345919
Background: Few adequately validated patient-reported outcome measures are available, which can assess recovery profiles following childbirth. Objective: We aimed to determine whether quantitative recovery (using the Obstetric Quality of Recovery-10...
8.
Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali J, Conner E, et al.
J Allergy Clin Immunol
. 2013 Jul;
132(1):101-9.
PMID: 23810097
Background: Patients with chronic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU) often continue to experience symptoms despite receiving standard-of-care therapy with H1-antihistamines along with 1 or more add-on therapies. Objectives: We sought...
9.
Opel A, Murray S, Kamath N, Dhinoja M, Abrams D, Sporton S, et al.
Heart Rhythm
. 2010 Feb;
7(3):340-3.
PMID: 20185106
Background: The treatment of choice for atrioventricular nodal reentrant tachycardia (AVNRT) is catheter ablation of the atrioventricular nodal slow pathway. Objective: The purpose of this study was to ascertain whether...